» Articles » PMID: 34827668

Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases

Overview
Journal Biomolecules
Publisher MDPI
Date 2021 Nov 27
PMID 34827668
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The inhibitors of two isoforms of mitogen-activated protein kinase-interacting kinases (i.e., MNK-1 and MNK-2) are implicated in the treatment of a number of diseases including cancer. This work reports, for the first time, a multi-target (or multi-tasking) in silico modeling approach (mt-QSAR) for probing the inhibitory potential of these isoforms against MNKs. Linear and non-linear mt-QSAR classification models were set up from a large dataset of 1892 chemicals tested under a variety of assay conditions, based on the Box-Jenkins moving average approach, along with a range of feature selection algorithms and machine learning tools, out of which the most predictive one (>90% overall accuracy) was used for mechanistic interpretation of the likely inhibition of MNK-1 and MNK-2. Considering that the latter model is suitable for virtual screening of chemical libraries-i.e., commercial, non-commercial and in-house sets, it was made publicly accessible as a ready-to-use FLASK-based application. Additionally, this work employed a focused kinase library for virtual screening using an mt-QSAR model. The virtual hits identified in this process were further filtered by using a similarity search, in silico prediction of drug-likeness, and ADME profiles as well as synthetic accessibility tools. Finally, molecular dynamic simulations were carried out to identify and select the most promising virtual hits. The information gathered from this work can supply important guidelines for the discovery of novel MNK-1/2 inhibitors as potential therapeutic agents.

Citing Articles

Shaping the Future of Obesity Treatment: In Silico Multi-Modeling of IP6K1 Inhibitors for Obesity and Metabolic Dysfunction.

Mondal I, Halder A, Pattanayak N, Mandal S, Cordeiro M Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399478 PMC: 10891520. DOI: 10.3390/ph17020263.


In Silico Modeling and Structural Analysis of Soluble Epoxide Hydrolase Inhibitors for Enhanced Therapeutic Design.

Sar S, Mitra S, Panda P, Mandal S, Ghosh N, Halder A Molecules. 2023; 28(17).

PMID: 37687207 PMC: 10490281. DOI: 10.3390/molecules28176379.


MNK Proteins as Therapeutic Targets in Leukemia.

Mazewski C, Platanias L Onco Targets Ther. 2023; 16:283-295.

PMID: 37113687 PMC: 10128080. DOI: 10.2147/OTT.S370874.


Support Vector Machine-Based Global Classification Model of the Toxicity of Organic Compounds to .

Wu F, Zhang X, Fang Z, Yu X Molecules. 2023; 28(6).

PMID: 36985675 PMC: 10057455. DOI: 10.3390/molecules28062703.


characterization of aryl benzoyl hydrazide derivatives as potential inhibitors of RdRp enzyme of H5N1 influenza virus.

Ghosh A, Panda P, Halder A, Cordeiro M Front Pharmacol. 2022; 13:1004255.

PMID: 36225563 PMC: 9548590. DOI: 10.3389/fphar.2022.1004255.


References
1.
Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R . MAP kinase-interacting kinases--emerging targets against cancer. Chem Biol. 2014; 21(4):441-452. DOI: 10.1016/j.chembiol.2014.01.011. View

2.
Lipinski C . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2014; 1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007. View

3.
Capecchi A, Probst D, Reymond J . One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome. J Cheminform. 2021; 12(1):43. PMC: 7291580. DOI: 10.1186/s13321-020-00445-4. View

4.
Diab S, Li P, Basnet S, Lu J, Yu M, Albrecht H . Unveiling new chemical scaffolds as Mnk inhibitors. Future Med Chem. 2016; 8(3):271-85. DOI: 10.4155/fmc.15.190. View

5.
Harvey M, De Fabritiis G . An Implementation of the Smooth Particle Mesh Ewald Method on GPU Hardware. J Chem Theory Comput. 2015; 5(9):2371-7. DOI: 10.1021/ct900275y. View